JPRN-jRCT2071220031已完成1 期
Drug-drug interaction study of NS-580 in Healthy male subjects (Phase I Study)
Higashioka Masaya0 个研究点目标入组 60 人开始时间: 2022年7月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 45age old（—）
- 性别
- Male
入选标准
- •1) Provided written informed consent
- •2) Japanese male subjects
- •3) Body mass index (BMI) >=18.5 and <25.0 kg/m2 at the time of screening tests and hospitalization
排除标准
- •1) Subjects with active systemic infections
- •2) Subjects with a history of drug and food allergies and hypersensitivity
- •3) Subjects who collected 200 mL or more of whole blood or component blood within 2 weeks before administration of the study drug
- •4) Subjects who are contraindicated for itraconazole, caffeine, triazolam, and rosuvastatin
研究者
相似试验
已完成
1 期
Clinical Pharmacology Study of NS-580 in Healthy female subjects (Phase I Study)endometriosisJPRN-jRCT2071220011Higashioka Masaya64
进行中（未招募）
2 期
A dose determination study of NS-580 in patients with endometriosis (late phase II)endometriosisJPRN-jRCT2031210685Higashioka Masaya372
已完成
2 期
An exploratory study of NS-580 in patients with endometriosis (early phase II)endometriosisJPRN-jRCT2080223592ippon Shinyaku Co., Ltd.150
已完成
1 期
Drug-drug interaction study of S-217622COVID-19JPRN-jRCT2031210595agata Tsutae14
未知
1 期
Drug-drug interaction study of SMP-508 and sitagliptin.JPRN-jRCT2080221771Dainippon Sumitomo Pharma Co., Ltd.24